Analysis of the concentration of selected serological parameters in patients undergoing
antibiotic treatment of Lyme disease and assessment of their potential application in the
control of the therapy effectiveness – pilot study

Tokarska-Rodak, Małgorzata; Fota-Markowska, Hanna; Pańczuk, Anna; Matuska, Katarzyna; Zarębska, Marta

doi:10.26444/aaem/132786

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IgG antibody to the C6 Bb peptide is a useful diagnostic biomarker but was not successful in indicating the effectiveness of antibiotic treatment ( 205 ). The gut microbiome from PTLD patients was compared to healthy controls and a computer model was able to identify PTLD patients solely based upon their microbiome profile ( 206 ).…”

Section: Next Generation Treatments and Biomarkersmentioning

confidence: 99%

Lyme disease and the pursuit of a clinical cure

Adkison

Embers

2023

Front. Med.

View full text Add to dashboard Cite

Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the United States. Many aspects of the disease are still topics of controversy within the scientific and medical communities. One particular point of debate is the etiology behind antibiotic treatment failure of a significant portion (10–30%) of Lyme disease patients. The condition in which patients with Lyme disease continue to experience a variety of symptoms months to years after the recommended antibiotic treatment is most recently referred to in the literature as post treatment Lyme disease syndrome (PTLDS) or just simply post treatment Lyme disease (PTLD). The most commonly proposed mechanisms behind treatment failure include host autoimmune responses, long-term sequelae from the initial Borrelia infection, and persistence of the spirochete. The aims of this review will focus on the in vitro, in vivo, and clinical evidence that either validates or challenges these mechanisms, particularly with regard to the role of the immune response in disease and resolution of the infection. Next generation treatments and research into identifying biomarkers to predict treatment responses and outcomes for Lyme disease patients are also discussed. It is essential that definitions and guidelines for Lyme disease evolve with the research to translate diagnostic and therapeutic advances to patient care.

show abstract

Section: Next Generation Treatments and Biomarkersmentioning

confidence: 99%